MCID: VSC003
MIFTS: 61

Visceral Leishmaniasis

Categories: Bone diseases, Endocrine diseases, Gastrointestinal diseases, Immune diseases, Infectious diseases

Aliases & Classifications for Visceral Leishmaniasis

MalaCards integrated aliases for Visceral Leishmaniasis:

Name: Visceral Leishmaniasis 12 15 17
Leishmaniasis, Visceral 45 74
Infection by Visceral Leishmaniasis 12
Leishmaniasis Visceral 56
Kala-Azar 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9146
ICD9CM 36 085.0
MeSH 45 D007898
NCIt 51 C34771
SNOMED-CT 69 48115004
ICD10 34 B55.0 B55.9
UMLS 74 C0023290

Summaries for Visceral Leishmaniasis

Disease Ontology : 12 A leishmaniasis that is the most severe form of the disease caused by protozoan parasites of the Leishmania genus, resulting in the infection of the internal organs such as liver, spleen and bone marrow. The symptoms include fever, weight loss, and an enlarged spleen and liver.

MalaCards based summary : Visceral Leishmaniasis, also known as leishmaniasis, visceral, is related to leishmaniasis and arthritis. An important gene associated with Visceral Leishmaniasis is IL10 (Interleukin 10), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Amphotericin B and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and bone, and related phenotypes are cellular and digestive/alimentary

Wikipedia : 77 Visceral leishmaniasis (VL), also known as kala-azar (UK: /ˌkɑːlə əˈzɑːr/), black fever, and Dumdum... more...

Related Diseases for Visceral Leishmaniasis

Diseases related to Visceral Leishmaniasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 405)
# Related Disease Score Top Affiliating Genes
1 leishmaniasis 32.5 IFNG IFNGR1 IL10 IL4 LMLN NOS2
2 arthritis 31.0 CXCL8 IFNG IL10 TNF
3 uveitis 30.9 IFNG IL10 IL4 TNF
4 human immunodeficiency virus infectious disease 30.9 IFNG IL10 IL2 TNF
5 hemophagocytic lymphohistiocytosis 30.9 CXCL8 IFNG IL10 TNF
6 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.7 FOXP3 IFNG IL10
7 lymphopenia 30.6 FOXP3 IFNG IL2
8 acquired immunodeficiency syndrome 30.6 ALB IFNG IL10 IL2 TNF
9 conjunctivitis 30.6 CXCL8 IFNG IL2 IL4
10 sleeping sickness 30.5 IL10 NOS2 PGD
11 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 30.5 FOXP3 IFNG IL10 IL2 IL4
12 myeloma, multiple 30.5 ALB CXCL8 IL2 TNF
13 rheumatic disease 30.4 IFNG IL10 TNF
14 mixed connective tissue disease 30.4 IFNG IL10 TNF
15 leptospirosis 30.4 CXCL8 IFNG IL10 TLR2 TNF
16 hematopoietic stem cell transplantation 30.3 IFNG IL10 IL2 TNF
17 toxoplasmosis 30.3 IFNG IL10 IL4 TLR2 TLR4 TNF
18 hepatopulmonary syndrome 30.2 ALB NOS2 TNF
19 fascioliasis 30.2 ALB IFNG IL10
20 hemorrhagic fever 30.1 ALB IFNG IL10 TNF
21 hepatitis a 30.1 ALB IFNG IL10 TNF
22 pneumonia 30.0 CXCL8 IL10 TLR2 TLR4 TNF
23 lepromatous leprosy 30.0 IFNG IFNGR1 IL10 IL2 TLR2 TNF
24 leprosy 3 30.0 IFNG IL10 IL2 SLC11A1 TLR2 TNF
25 aphthous stomatitis 29.9 IL10 IL2 IL4 TLR2 TNF
26 tuberculous meningitis 29.9 CXCL8 TLR2 TNF
27 bacterial infectious disease 29.8 CXCL8 IFNG IL10 SLC11A1 TLR2 TLR4
28 endocarditis 29.7 ALB CXCL8 IL10 TLR2 TNF
29 bacterial sepsis 29.7 CXCL8 IL10 NOS2 TLR4 TNF
30 chagas disease 29.7 CXCL8 IFNG IL10 IL2 NOS2 TLR2
31 osteomyelitis 29.6 CXCL8 IFNG IFNGR1 IL10 TNF
32 systemic lupus erythematosus 29.6 ALB FOXP3 IFNG IL10 IL2 IL4
33 pulmonary tuberculosis 29.6 IFNG IFNGR1 IL10 IL2 IL4 SLC11A1
34 meningitis 29.6 ALB CXCL8 IFNG IL10 TLR2 TNF
35 cutaneous leishmaniasis 29.4 FOXP3 IFNG IL10 IL4 LMLN PGD
36 typhoid fever 29.4 ALB IFNG IFNGR1 SLC11A1 TLR4 TNF
37 filariasis 29.4 ALB IFNG IL10 IL2 TLR2 TLR4
38 trypanosomiasis 29.4 ALB CXCL8 IFNG IL10 IL2 IL4
39 rheumatoid arthritis 29.4 CXCL8 FOXP3 IFNG IL10 IL2 IL4
40 common variable immunodeficiency 29.3 FOXP3 IFNG IL10 IL2 IL4 TLR2
41 multiple sclerosis 29.2 FOXP3 IFNG IL10 IL2 IL4 NOS2
42 colitis 28.7 CXCL8 FOXP3 IFNG IL10 IL2 IL4
43 malaria 28.6 ALB CXCL8 FOXP3 IFNG IFNGR1 IL10
44 kala-azar 2 12.5
45 kala-azar 3 12.5
46 kala-azar 1 11.7
47 cephalosporin allergy 10.6 IFNG IL10
48 b-cell growth factor 10.6 IFNG IL4
49 sporotrichosis 10.6 IFNG IL10
50 autoimmune myocarditis 10.5 IFNG TNF

Graphical network of the top 20 diseases related to Visceral Leishmaniasis:



Diseases related to Visceral Leishmaniasis

Symptoms & Phenotypes for Visceral Leishmaniasis

MGI Mouse Phenotypes related to Visceral Leishmaniasis:

47 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.35 ALB EEF2 FOXP3 IFNG IFNGR1 IL10
2 digestive/alimentary MP:0005381 10.34 ALB FOXP3 IFNG IFNGR1 IL10 IL2
3 hematopoietic system MP:0005397 10.34 FOXP3 IFNG IFNGR1 IL10 IL2 IL27
4 homeostasis/metabolism MP:0005376 10.32 ALB FOXP3 IFNG IFNGR1 IL10 IL2
5 immune system MP:0005387 10.31 FOXP3 IFNG IFNGR1 IL10 IL2 IL27
6 mortality/aging MP:0010768 10.31 ALB EEF2 FOXP3 IFNG IFNGR1 IL10
7 growth/size/body region MP:0005378 10.28 EEF2 FOXP3 IFNG IL10 IL2 IL4
8 endocrine/exocrine gland MP:0005379 10.25 ALB FOXP3 IFNG IFNGR1 IL10 IL2
9 cardiovascular system MP:0005385 10.23 FOXP3 IFNG IFNGR1 IL10 IL2 NOS2
10 liver/biliary system MP:0005370 10.2 ALB FOXP3 IFNG IFNGR1 IL10 IL2
11 integument MP:0010771 10.13 FOXP3 IFNG IFNGR1 IL10 IL4 NOS2
12 neoplasm MP:0002006 10.1 ALB IFNG IFNGR1 IL10 IL2 NOS2
13 normal MP:0002873 9.97 ALB FOXP3 IFNG IL10 IL4 TLR2
14 renal/urinary system MP:0005367 9.92 ALB FOXP3 IFNG IFNGR1 IL4 NOS2
15 reproductive system MP:0005389 9.91 FOXP3 IFNG IFNGR1 IL10 IL2 IL4
16 respiratory system MP:0005388 9.81 FOXP3 IFNG IL10 IL2 IL4 NOS2
17 skeleton MP:0005390 9.61 IFNG IFNGR1 IL10 IL4 NOS2 PGD
18 vision/eye MP:0005391 9.23 FOXP3 IFNG IL10 IL2 IL4 NOS2

Drugs & Therapeutics for Visceral Leishmaniasis

Drugs for Visceral Leishmaniasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 73)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1397-89-3 14956 5280965
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
3
Miltefosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58066-85-6 3600
4
deoxycholic acid Approved Phase 4,Phase 3,Not Applicable 83-44-3 222528
5
Paromomycin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 1263-89-4, 7542-37-2 165580
6
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
7
meglumine antimoniate Experimental, Investigational Phase 4,Early Phase 1 133-51-7
8 Liposomal amphotericin B Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
12 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Gastrointestinal Agents Phase 4,Phase 3,Not Applicable
15 Amphotericin B, deoxycholate drug combination Phase 4,Phase 3,Not Applicable
16 Cholagogues and Choleretics Phase 4,Phase 3,Not Applicable
17 Anthelmintics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Antimony Sodium Gluconate Phase 4,Phase 3,Phase 2,Phase 1
19 Anesthetics Phase 4
20
Pentamidine Approved, Investigational Phase 3 100-33-4 4735
21
Aluminum sulfate Approved Phase 2, Phase 3,Phase 3 10043-01-3
22
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
23
tannic acid Approved Phase 3 1401-55-4
24
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
25
Tocopherol Approved, Investigational Phase 3 1406-66-2 14986
26
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
27 Tocotrienol Investigational Phase 3 6829-55-6
28 Antiviral Agents Phase 3,Not Applicable
29 Immunologic Factors Phase 2, Phase 3,Phase 3,Phase 1
30 Vaccines Phase 2, Phase 3,Phase 3,Phase 1
31 Adjuvants, Immunologic Phase 2, Phase 3,Phase 3
32 Analgesics Phase 3
33 Anti-Retroviral Agents Phase 3
34 Analgesics, Non-Narcotic Phase 3
35 Anti-HIV Agents Phase 3
36 Interleukin-2 Phase 3
37 Peripheral Nervous System Agents Phase 3
38 Vitamins Phase 3,Not Applicable
39 Tocopherols Phase 3
40 Tocotrienols Phase 3
41 Soybean oil, phospholipid emulsion Phase 2
42 Pharmaceutical Solutions Phase 2
43 Fat Emulsions, Intravenous Phase 2
44 Parenteral Nutrition Solutions Phase 2
45 Soy Bean Phase 2
46 Immunoglobulins Phase 1, Phase 2,Not Applicable
47 Antibodies Phase 1, Phase 2,Not Applicable
48 Thromboplastin Phase 1
49
Acetylcysteine Approved, Investigational Not Applicable 616-91-1 12035
50
Coal tar Approved Not Applicable 8007-45-2

Interventional clinical trials:

(show top 50) (show all 63)
# Name Status NCT ID Phase Drugs
1 Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis Unknown status NCT01566552 Phase 4 AMBISOME
2 Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children Completed NCT01032187 Phase 4 Meglumine antimoniate;Amphotericin B-deoxycholate
3 Expand Access/Assess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral Leishmaniasis Completed NCT00604955 Phase 4 Paromomycin sulfate
4 A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL) Completed NCT01975051 Phase 4 Mitefosine
5 Safety and Effectiveness of Short-course AmBisome in the Treatment of PKDL in Bangladesh Completed NCT03311607 Phase 4 AmBisome
6 Efficacy of Radio-frequency Induced Heat (RFH)Therapy in Treatment of Cutaneous Leishmaniasis in India Completed NCT01661296 Phase 4 Sodium stibogluconate
7 Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil Terminated NCT01310738 Phase 4 Antimoniate of N-methylglucamine;amphotericin B deoxycholate;Liposomal amphotericin B;Liposomal amphotericin B;Antimoniate of N-methylglucamine
8 Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients. Unknown status NCT02011958 Phase 3 Liposomal Amphotericin B;Miltefosine
9 An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leishmaniasis Completed NCT00629031 Phase 3 Paromomycin;Paromomycin
10 Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis Completed NCT00628719 Phase 3 Liposomal Amphotericin B;amphotericin B deoxycholate
11 Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study Completed NCT01360762 Phase 3 Pentamidine
12 Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis Completed NCT00696969 Phase 3 Amphotericin B Deoxycholate;Ambisome + Miltefosine;Ambisome and Paromomycin;Miltefosine and Paromomycin
13 Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis Completed NCT00216346 Phase 3 Paromomycin sulfate;Amphotericin B
14 To Study the Effect Of Single Infusions Of Amphotericin B Lipid Preparations in Treatment of Patients Of Kala Azar Completed NCT00876824 Phase 3 Amphotericin B Lipid emulsion;Liposomal Amphotericin B
15 Replacement of Insecticides to Control Visceral Leishmaniasis (VL) Completed NCT01644682 Phase 3
16 Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis Completed NCT00255567 Phase 3 Sodium Stibogluconate;Paromomycin sulphate;SSG and Paromomycin sulphate
17 Combination Therapy in Indian Visceral Leishmaniasis Completed NCT00523965 Phase 3 amphotericin B deoxycholate;Liposomal Amphotericin B with Miltefosine;Liposomal Amphotericin B and Paromomycin Sulfate;miltefosine + Paromomycin sulfate
18 Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh Completed NCT01122771 Phase 3 Liposomal amphotericin B;liposomal amphotericin B + miltefosine;liposomal amphotericin B + paromomycin;Miltefosine + Paromomycin
19 Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With Positive Response to Leishmanin (LST>0) Completed NCT00429780 Phase 2, Phase 3
20 Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With no Response to Leishmanin Completed NCT00429715 Phase 2, Phase 3
21 An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy Completed NCT00004978 Phase 3 Recombinant interleukin-2 (rIL-2)
22 Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study) Completed NCT00013611 Phase 3 Proleukin
23 Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa Recruiting NCT03129646 Phase 3 Miltefosine;Paromomycin;Sodium stibogluconate
24 Miltefosine for Children With PKDL Recruiting NCT02193022 Phase 3 Miltefosine
25 A Phase II Study To Assess Safety and Efficacy Of Short-Course Regimens Of Amphotericin B Emulsion In Kala-Azar Completed NCT00497601 Phase 2 Amphotericin B fat emulsion in visceral leishmaniasis;Amphotericin B fat emulsion;Amphotericin B in fat emulsion
26 Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and AmBisome® Combination, Miltefosine and AmBisome® and Miltefosine Alone for the Treatment Visceral Leishmaniasis in Eastern Africa Completed NCT01067443 Phase 2 Liposomal amphotericin B (AmBisome®) and sodium stibogluconate;Liposomal amphotericin B + miltefosine;Miltefosine
27 Pharmacokinetics/Safety of Miltefosine Allometric Dose for the Treatment of Visceral Leishmaniasis in Children in Eastern Africa Completed NCT02431143 Phase 2 Miltefosine
28 Short Course of Miltefosine and Liposomal Amphotericin B for Kala-azar Completed NCT00371995 Phase 2 Liposomal amphotericin B and Miltefosine
29 Combination Chemotherapy for the Treatment of Indian Kala-Azar Completed NCT00370825 Phase 2 Combination therapy with AmBisome and miltefosine
30 A Study Evaluating Sitamaquine Compared With Amphotericin B In The Treatment Of Visceral Leishmaniasis. Completed NCT00381394 Phase 2 sitamaquine
31 Sodium Stibogluconate Treatment of Leishmaniasis Completed NCT00662012 Phase 2 Sodium Stibogluconate (SSG)
32 Safety and Efficacy of Oral Miltefosine in Patients With Post Kala Azar Dermal Leishmaniasis (PKDL) Completed NCT01635777 Phase 2 Miltefosine;Miltefosine
33 Use of Sodium Stibogluconate as a Treatment for Leishmaniasis Completed NCT00657618 Phase 1, Phase 2 Sodium Stibogluconate (SSG)
34 Short Course Regimens for Treatment of PKDL (Sudan) Recruiting NCT03399955 Phase 2 Paromomycin;Ambisome;Miltefosine
35 Thermotherapy + a Short Course of Miltefosine for the Treatment of Uncomplicated Cutaneous Leishmaniasis in the New World¨ Active, not recruiting NCT02687971 Phase 2 Miltefosine
36 A Study of a New Leishmania Vaccine Candidate ChAd63-KH Active, not recruiting NCT02894008 Phase 2 ChAd63-KH
37 Trial to Determine Efficacy of Fexinidazole in Visceral Leihmaniasis Patients in Sudan Terminated NCT01980199 Phase 2 Fexinidazole
38 Miltefosine for Brazilian Visceral Leishmaniasis Terminated NCT00378495 Phase 1, Phase 2 Miltefosine: initially 2.5 mg/kg/day for 28 days
39 Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Patients With VL Terminated NCT00832208 Phase 2 Liposomal amphotericin B (Ambisome);Liposomal amphotericin B (Ambisome)
40 SCH708980 With and Without AmBisome for Visceral Leishmaniasis Withdrawn NCT01437020 Phase 1, Phase 2 SCH708980 Anti-IL-10 monoclonal;AmBisome
41 Open-Label Safety Study of Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE in Healthy Adults in India Completed NCT00486382 Phase 1
42 Phase 1 LEISH-F3 + SLA-SE Vaccine Trial in Healthy Adult Volunteers Completed NCT02071758 Phase 1
43 Safety and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine With SSG for Patients With PKDL Completed NCT00982774 Phase 1
44 Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult Volunteers Completed NCT01484548 Phase 1
45 Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition Recruiting NCT03636659 Phase 1 Amphotericin B Liposome;AmBisome (Amphotericin B) Liposome
46 Immune Response of Visceral Leishmaniasis PatientsTreated With Antimonial Plus N-Acetylcysteine Unknown status NCT01138956 Not Applicable N-acetylcysteine;Pentavalent antimonial
47 Visceral Leishmaniasis and Malnutrition in Amhara Regional State, Ethiopia Completed NCT02148822
48 A Pilot Study for Capacity Building for a Multi-centre, Randomized Trial for Treatment of Kala Azar in Bangladesh Completed NCT01240473 Not Applicable Randomized trial for treatment of kala azar in Bangladesh
49 Immunogenetics of Visceral Leishmaniasis Completed NCT00342823
50 An Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh Completed NCT01328457 Not Applicable Paromomycin sulfate

Search NIH Clinical Center for Visceral Leishmaniasis

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: leishmaniasis, visceral

Genetic Tests for Visceral Leishmaniasis

Anatomical Context for Visceral Leishmaniasis

MalaCards organs/tissues related to Visceral Leishmaniasis:

42
Testes, T Cells, Bone, Bone Marrow, Spleen, Liver, Skin

Publications for Visceral Leishmaniasis

Articles related to Visceral Leishmaniasis:

(show top 50) (show all 3072)
# Title Authors Year
1
Visceral Leishmaniasis and Glomerulonephritis: A Case Report. ( 30787856 )
2019
2
Association between Insulin-Like Growth Factor-I Levels and the Disease Progression and Anemia in Visceral Leishmaniasis. ( 30761980 )
2019
3
A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia. ( 30653490 )
2019
4
Unusual manifestations of visceral leishmaniasis in children: a case series and its spatial dispersion in the western region of São Paulo state, Brazil. ( 30658589 )
2019
5
Eliminating visceral leishmaniasis in South Asia: the road ahead. ( 30670453 )
2019
6
Visceral Leishmaniasis. ( 30673546 )
2019
7
Comorbid infections induce progression of visceral leishmaniasis. ( 30674329 )
2019
8
Mannosylated thiolated paromomycin-loaded PLGA nanoparticles for the oral therapy of visceral leishmaniasis. ( 30688557 )
2019
9
Leishmania infantum recombinant kinesin degenerated derived repeat (rKDDR): A novel potential antigen for serodiagnosis of visceral leishmaniasis. ( 30703138 )
2019
10
PD-1 and PD-L1 regulate cellular immunity in canine visceral leishmaniasis. ( 30711051 )
2019
11
Visceral Leishmaniasis: Recent Advances in Diagnostics and Treatment Regimens. ( 30712769 )
2019
12
Modulation of the immune response and infection pattern to Leishmania donovani in visceral leishmaniasis due to arsenic exposure: An in vitro study. ( 30721235 )
2019
13
Improving the reference standard for the diagnosis of canine visceral leishmaniasis: a challenge for current and future tests. ( 30726343 )
2019
14
Evaluation of three recombinant proteins for the development of ELISA and immunochromatographic tests for visceral leishmaniasis serodiagnosis. ( 30726344 )
2019
15
Visceral leishmaniasis in a patient with lung tumour: a case report. ( 30727854 )
2019
16
Use of miltefosine to treat canine visceral leishmaniasis caused by Leishmania infantum in Brazil. ( 30736866 )
2019
17
Intestinal Nematode Infection Exacerbates Experimental Visceral Leishmaniasis. ( 30742324 )
2019
18
Re-Emerging foci of visceral leishmaniasis in Armenia - first molecular diagnosis of clinical samples. ( 30755288 )
2019
19
A chronic bioluminescent model of experimental visceral leishmaniasis for accelerating drug discovery. ( 30763330 )
2019
20
Visceral leishmaniasis with haemophagocytic lymphohistiocytosis. ( 30765439 )
2019
21
Focal spleen lesions in visceral leishmaniasis, a neglected manifestation of a neglected disease: report of three cases and systematic review of literature. ( 30771194 )
2019
22
First isolation of Leishmania infantum by blood culture in bovines from endemic area for canine visceral leishmaniasis. ( 30782228 )
2019
23
Development of a multiplexed assay for the detection of Leishmania donovani/Leishmania infantum protein biomarkers in the urine of patients with visceral leishmaniasis. ( 30787142 )
2019
24
Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia. ( 30789910 )
2019
25
Visceral leishmaniasis: amastigotes in the bone marrow. ( 30793113 )
2019
26
Abnormal B-Cell Subset and Blimp-1-Mediated Humoral Responses Associated With Visceral Leishmaniasis Pathogenesis. ( 30793688 )
2019
27
IL-2 is an upstream regulator of CD4+ T cells from visceral leishmaniasis patients with therapeutic potential. ( 30796820 )
2019
28
The diagnosis of canine visceral leishmaniasis in Brazil: confronting old problems. ( 30796913 )
2019
29
Efficacy of lapachol on treatment of cutaneous and visceral leishmaniasis. ( 30797783 )
2019
30
Visceral leishmaniasis mimicking systemic lupus erythematosus. ( 30810652 )
2019
31
Visceral leishmaniasis in pregnant women from Rio Grande do Norte, Brazil: A case report and literature review. ( 30810655 )
2019
32
Performance evaluation of anti-fixed Leishmania infantum promastigotes immunoglobulin G (IgG) detected by flow cytometry as a diagnostic tool for visceral Leishmaniasis. ( 30817916 )
2019
33
Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis. ( 30817917 )
2019
34
Pam3CSK4 adjuvant given intranasally boosts anti-Leishmania immunogenicity but not protective immune responses conferred by LaAg vaccine against visceral leishmaniasis. ( 30817996 )
2019
35
Dynamic spatiotemporal modeling of the infected rate of visceral leishmaniasis in human in an endemic area of Amhara regional state, Ethiopia. ( 30822344 )
2019
36
Insecticide-impregnated dog collars reduce infantile clinical visceral leishmaniasis under operational conditions in NW Iran: A community-wide cluster randomised trial. ( 30830929 )
2019
37
Evaluation of synergistic therapeutic effect of shark cartilage extract with artemisinin and glucantime on visceral leishmaniasis in BALB/c mice. ( 30834079 )
2019
38
Malaria-visceral leishmaniasis co-infection and associated factors among migrant laborers in West Armachiho district, North West Ethiopia: community based cross-sectional study. ( 30849958 )
2019
39
A co-infection with malaria and visceral leishmaniasis in Eastern state of India. ( 30853284 )
2019
40
Walking a tightrope: drug discovery in visceral leishmaniasis. ( 30876846 )
2019
41
Understanding Resistance vs. Susceptibility in Visceral Leishmaniasis Using Mouse Models of Leishmania infantum Infection. ( 30881923 )
2019
42
Visceral leishmaniasis in a patient with systemic lupus erythematosus from Colombia, Latin America. ( 30882389 )
2019
43
Prevalence of HIV and associated factors among visceral leishmaniasis cases in an endemic area of Northeast Brazil. ( 30892399 )
2019
44
Atypical clinical presentation of visceral leishmaniasis: a rare case without splenomegaly. ( 30895886 )
2019
45
Crosstalk of PD-1 signaling with SIRT1/FOXO-1 axis in progression of visceral leishmaniasis. ( 30910830 )
2019
46
Lower levels of leptin are associated with severity parameters in visceral leishmaniasis patients. ( 30913261 )
2019
47
HLA-DR Class II expression on myeloid and lymphoid cells in relation to HLA-DRB1 as a genetic risk factor for visceral leishmaniasis. ( 30403401 )
2019
48
Integrating Case Detection of Visceral Leishmaniasis and Other Febrile Illness with Vector Control in the Post-Elimination Phase in Nepal. ( 30426921 )
2019
49
Intervention Packages for Early Visceral Leishmaniasis Case Detection and Sandfly Control in Bangladesh: A Comparative Analysis. ( 30457088 )
2019
50
Culling Dogs for Zoonotic Visceral Leishmaniasis Control: The Wind of Change. ( 30554966 )
2019

Variations for Visceral Leishmaniasis

Expression for Visceral Leishmaniasis

Search GEO for disease gene expression data for Visceral Leishmaniasis.

Pathways for Visceral Leishmaniasis

Pathways related to Visceral Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.07 CXCL8 EEF2 IFNG IFNGR1 IL10 IL2
2
Show member pathways
13.73 CXCL8 IFNG IFNGR1 IL10 IL2 IL27
3
Show member pathways
13.43 CXCL8 IL10 IL2 IL4 TLR2 TLR4
4
Show member pathways
13.41 CXCL8 IFNG IFNGR1 IL10 IL2 IL27
5
Show member pathways
13.26 IFNG IFNGR1 IL2 IL4 TLR2 TLR4
6
Show member pathways
13.22 CXCL8 IFNG IFNGR1 IL10 IL2 NOS2
7
Show member pathways
12.96 CXCL8 FOXP3 IFNG IFNGR1 IL10 IL2
8 12.9 CXCL8 IFNG IFNGR1 IL2 IL4 NOS2
9
Show member pathways
12.71 IFNG IFNGR1 IL10 IL2 IL4 TNF
10
Show member pathways
12.65 IFNG IL10 IL2 NOS2 TNF
11
Show member pathways
12.64 CXCL8 IFNG IFNGR1 IL2 IL4 TLR2
12 12.63 FOXP3 IFNG IL10 IL2 IL4 TLR2
13
Show member pathways
12.58 IFNG IFNGR1 IL2 IL4 TNF
14
Show member pathways
12.51 FOXP3 IFNG IFNGR1 IL10 IL2 IL4
15
Show member pathways
12.5 IFNG IL10 IL2 IL4 TNF
16
Show member pathways
12.47 IFNG IFNGR1 IL10 IL2 IL4
17
Show member pathways
12.41 ALB IFNG IL2 IL4 TNF
18
Show member pathways
12.41 CXCL8 IFNG IL4 TLR2 TNF
19
Show member pathways
12.41 CXCL8 IFNG IFNGR1 NOS2 TLR4 TNF
20
Show member pathways
12.34 CXCL8 IFNG IL10 IL2 IL4 TNF
21
Show member pathways
12.31 CXCL8 TLR2 TLR4 TNF
22 12.29 IFNG IFNGR1 IL10 NOS2 TLR2 TLR4
23
Show member pathways
12.27 CXCL8 NOS2 TLR2 TNF
24
Show member pathways
12.26 IFNG IFNGR1 TLR4 TNF
25 12.26 IFNG IFNGR1 NOS2 TLR2 TLR4 TNF
26
Show member pathways
12.15 CXCL8 IFNG IFNGR1 IL10 IL2 IL4
27
Show member pathways
12.14 IFNG IL4 TLR2 TLR4 TNF
28
Show member pathways
12.13 IFNG IFNGR1 IL10 IL4 NOS2 TLR2
29 12.09 IFNG IL10 IL2 IL4 TNF
30 12.08 CXCL8 IL10 IL4 NOS2 TNF
31
Show member pathways
12.05 IFNG IL2 IL4 NOS2
32 12.03 CXCL8 IFNG IL2 IL4 NOS2 TLR4
33 11.99 IFNG IFNGR1 NOS2 TLR4
34 11.97 CXCL8 IFNG TLR2 TLR4 TNF
35 11.95 IFNG IFNGR1 IL10 IL2
36 11.94 CXCL8 IFNG IFNGR1 NOS2 TLR4
37 11.9 CXCL8 TLR4 TNF
38 11.89 CXCL8 IL2 TLR4
39 11.89 CXCL8 IFNG IL2 IL4
40 11.89 IFNG IL10 IL2 IL4 TNF
41
Show member pathways
11.88 CXCL8 FOXP3 TLR4
42 11.86 CXCL8 IL10 NOS2 TLR4 TNF
43 11.84 IFNG IL10 IL2 TNF
44
Show member pathways
11.81 CXCL8 FOXP3 IFNG IL2 IL4 TNF
45
Show member pathways
11.78 CXCL8 IFNG IFNGR1 IL4 NOS2 TLR2
46 11.76 IFNG IL10 IL2 IL4 NOS2 TNF
47
Show member pathways
11.74 FOXP3 IL2 IL4
48
Show member pathways
11.74 CXCL8 IFNG IL2 NOS2 TNF
49 11.71 CXCL8 IL4 TNF
50
Show member pathways
11.69 IFNG IL2 TNF

GO Terms for Visceral Leishmaniasis

Cellular components related to Visceral Leishmaniasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 ALB CXCL8 EEF2 IFNG IL10 IL2
2 extracellular space GO:0005615 9.28 ALB CXCL8 IFNG IL10 IL2 IL27

Biological processes related to Visceral Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Name GO ID Score Top Affiliating Genes
1 defense response to bacterium GO:0042742 9.97 IL10 NOS2 SLC11A1 TLR4 TNF
2 regulation of signaling receptor activity GO:0010469 9.95 CXCL8 IFNG IL10 IL2 IL27 IL4
3 response to bacterium GO:0009617 9.91 IL27 NOS2 SLC11A1 TLR4
4 response to virus GO:0009615 9.91 FOXP3 IFNG IFNGR1 TNF
5 response to lipopolysaccharide GO:0032496 9.91 IL10 NOS2 SLC11A1 TLR2 TLR4
6 cellular response to interferon-gamma GO:0071346 9.89 NOS2 TLR2 TLR4
7 cellular response to lipopolysaccharide GO:0071222 9.89 CXCL8 IL10 NOS2 TLR4 TNF
8 defense response to Gram-negative bacterium GO:0050829 9.88 NOS2 SLC11A1 TLR4
9 positive regulation of gene expression GO:0010628 9.87 FOXP3 IFNG IL4 SLC11A1 TLR2 TLR4
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.86 IFNG IL2 IL4
11 regulation of insulin secretion GO:0050796 9.86 IFNG NOS2 TNF
12 positive regulation of interleukin-6 production GO:0032755 9.85 TLR2 TLR4 TNF
13 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.84 TLR2 TLR4 TNF
14 positive regulation of inflammatory response GO:0050729 9.84 IL2 TLR2 TLR4 TNF
15 negative regulation of tumor necrosis factor production GO:0032720 9.83 FOXP3 IL10 TLR4
16 positive regulation of nitric oxide biosynthetic process GO:0045429 9.83 IFNG TLR4 TNF
17 positive regulation of B cell proliferation GO:0030890 9.81 IL2 IL4 TLR4
18 lipopolysaccharide-mediated signaling pathway GO:0031663 9.81 TLR2 TLR4 TNF
19 inflammatory response GO:0006954 9.8 CXCL8 IL10 IL27 SLC11A1 TLR2 TLR4
20 negative regulation of interferon-gamma production GO:0032689 9.79 FOXP3 IL10 TLR4
21 positive regulation of interleukin-8 production GO:0032757 9.77 TLR2 TLR4 TNF
22 positive regulation of interleukin-12 production GO:0032735 9.74 IFNG TLR2 TLR4
23 positive regulation of interferon-gamma production GO:0032729 9.73 IL2 SLC11A1 TLR4 TNF
24 negative regulation of growth of symbiont in host GO:0044130 9.72 IL10 TNF
25 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.72 IL10 TNF
26 positive regulation of chemokine production GO:0032722 9.72 TLR2 TLR4 TNF
27 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.71 TLR2 TLR4
28 regulation of cytokine secretion GO:0050707 9.71 TLR2 TLR4
29 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.71 IFNG IFNGR1
30 I-kappaB phosphorylation GO:0007252 9.71 TLR2 TLR4
31 positive regulation of regulatory T cell differentiation GO:0045591 9.7 FOXP3 IL2
32 macrophage activation GO:0042116 9.7 SLC11A1 TLR4
33 regulation of regulatory T cell differentiation GO:0045589 9.7 FOXP3 IFNG IL2
34 cellular response to lipoteichoic acid GO:0071223 9.69 TLR2 TLR4
35 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.69 TLR4 TNF
36 positive regulation of isotype switching to IgG isotypes GO:0048304 9.69 IL2 IL4
37 endothelial cell apoptotic process GO:0072577 9.68 IL10 TNF
38 negative regulation of T-helper 17 cell differentiation GO:2000320 9.68 FOXP3 IL2
39 negative regulation of cytokine secretion involved in immune response GO:0002740 9.67 IL10 TNF
40 negative regulation of lymphocyte proliferation GO:0050672 9.67 FOXP3 IL2
41 positive regulation of killing of cells of other organism GO:0051712 9.65 IFNG NOS2
42 regulation of isotype switching GO:0045191 9.65 IL10 IL4
43 negative regulation of interleukin-17 production GO:0032700 9.65 FOXP3 IFNG TLR4
44 type 2 immune response GO:0042092 9.64 IL10 IL4
45 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.63 IFNG TNF
46 response to molecule of bacterial origin GO:0002237 9.63 CXCL8 IL10 TLR2
47 receptor biosynthetic process GO:0032800 9.62 IL10 TNF
48 positive regulation of cellular response to macrophage colony-stimulating factor stimulus GO:1903974 9.59 TLR2 TLR4
49 positive regulation of vitamin D biosynthetic process GO:0060557 9.58 IFNG TNF
50 positive regulation of MHC class II biosynthetic process GO:0045348 9.54 IL10 IL4 TLR4

Molecular functions related to Visceral Leishmaniasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.17 CXCL8 IFNG IL10 IL2 IL27 IL4
2 lipopolysaccharide receptor activity GO:0001875 8.96 TLR2 TLR4

Sources for Visceral Leishmaniasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....